Compare AstraZeneca plc (AZN) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs PAGSEG Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while PAGSEG Inc trades at $8.7 (market cap $2.48B). The key difference: AstraZeneca plc is far larger — about 100.1× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.7%). Which is the better fit depends on your goals.
| AZN | PAGS | |
|---|---|---|
Market Cap | $248.14B | $2.48B |
Sector | Health | Technology |
52-Week High | $209.48 | $12.00 |
52-Week Low | $147.06 | $8.38 |
Enterprise Value | $275.41B | $10.22B |
Dividend Yield | 2.01% | 11.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
PAGS trades at $8.72, down 3.96% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The stock presents compelling value with a P/E of 6.17 and P/B of 0.87, supported by strong profitability metrics including 53.05% gross margin and 14.52% ROE. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while Q1 2026 showed a slight miss.
Analyst consensus remains bullish with 62.5% buy ratings and a $11.45 price target, suggesting 31% upside potential. Key risks include competitive pressures in Brazil's digital banking sector and macroeconomic sensitivity to interest rate cycles. The company maintains solid cash flow generation with $7.56B operating cash flow in 2025, supporting ongoing business expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
